Compare Amphastar Pharmaceuticals Inc (AMPH) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Fidelity National Information Servcs Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.35 (market cap $826.08M), while Fidelity National Information Servcs Inc trades at $42.39 (market cap $21.70B). The key difference: Fidelity National Information Servcs Inc is far larger — about 26.3× Amphastar Pharmaceuticals Inc's market cap, and Fidelity National Information Servcs Inc pays a 4% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | FIS | |
|---|---|---|
Market Cap | $826.08M | $21.70B |
Sector | Health | Technology |
52-Week High | $30.81 | $81.94 |
52-Week Low | $16.87 | $37.72 |
Enterprise Value | $1.22B | $42.09B |
Dividend Yield | — | 4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
FIS trades at $41.98, up 0.89% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 2026, and the company shows improving profitability with a 23.35% net income margin. Positive news includes cloud banking deals with Frankfurt International Bank and First Commerce Bank, reinforcing growth in digital banking services. The stock trades below the consensus price target of $52.57, indicating potential upside.
The outlook for FIS is positive due to strategic cloud expansions and earnings momentum, but risks include high debt levels and macroeconomic pressures on lending. Wall Street consensus is bullish with 58% buy ratings, though investors should monitor debt management and competitive threats in the fintech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
